UNSPSC 51281807: Amrubicin

This classification denotes an anthracycline antibiotic with the molecular formula C25H25NO9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 93N13LB4Z2, chemically known as ( -)-(7s,9s)-9-acetyl-9-amino-7-((2-deoxy-beta-d-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione but generally known as amrubicin, which bears US NIH Compound Identifier 178149. Amrubicin most often comes in base and hydrochloride forms.

UNSPSC 51281807 Amrubicin, a Commodity code, shows minimal relevant recent activity in state and local procurement. The code nominally covers amrubicin, a chemotherapy agent, yet the four recent opportunities posted under this code involve naloxone, safe drug deactivation systems, generic pharmaceuticals, over-the-counter products, and medical/first aid supplies—none of which are amrubicin. State and local health departments, counties, and cooperative purchasing alliances are the primary issuing bodies visible in recent postings, but the mismatch between the code's nominal scope and the actual goods being solicited suggests either data classification error or inconsistent tagging by the jurisdictions posting these opportunities. The code does not appear to track meaningful amrubicin procurement activity at the state and local level.

Geographic activity spans Florida (Seminole County), Texas (HHS Commission), Minnesota (MMCAP serving multiple states including Oregon), and Florida again (City of Tampa). The most recent dated opportunity is the Tampa Fire Department's March 2026 IFB for medical and first aid supplies ($700,000 estimated value, SLBE set-aside), followed by the Minnesota MMCAP RFP for generic pharmaceuticals and OTC products (due March 26, 2026, two-year term with optional extensions). Neither operation involves amrubicin procurement. Unless the code is being used as a catch-all for chemotherapy or oncology-related drugs at specific jurisdictions, the data does not support the conclusion that state and local governments are actively procuring amrubicin under this classification.